Literature DB >> 16164409

GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways.

Stefan Hart1, Oliver M Fischer, Norbert Prenzel, Esther Zwick-Wallasch, Matthias Schneider, Lothar Hennighausen, Axel Ullrich.   

Abstract

The epidermal growth factor receptor (EGFR) plays a key role in the regulation of important cellular processes under normal and pathophysiological conditions such as cancer. In human mammary carcinomas the EGFR is involved in regulating cell growth, survival, migration and metastasis and its activation correlates with the lack of response in hormone therapy. Here, we demonstrate in oestrogen receptor-positive and -negative human breast cancer cells and primary mammary epithelial cells a cross-communication between G protein-coupled receptors (GPCRs) and the EGFR. We present evidence that specific inhibition of ADAM15 or TACE blocks GPCR-induced and proHB-EGF-mediated EGFR tyrosine phosphorylation, downstream mitogenic signalling and cell migration. Notably, activation of the PI3K downstream mediator PKB/Akt by GPCR ligands involves the activity of sphingosine kinase (SPHK) and is independent of EGFR signal transactivation. We conclude that GPCR-induced chemotaxis of breast cancer cells is mediated by EGFR-dependent and -independent signalling pathways, with both parallel pathways having to act in concert to achieve a complete migratory response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16164409     DOI: 10.1515/BC.2005.099

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  35 in total

1.  ADAM15 protein amplifies focal adhesion kinase phosphorylation under genotoxic stress conditions.

Authors:  Dorothee Fried; Beate B Böhm; Kristin Krause; Harald Burkhardt
Journal:  J Biol Chem       Date:  2012-04-27       Impact factor: 5.157

Review 2.  G protein-coupled receptors: novel targets for drug discovery in cancer.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Nat Rev Drug Discov       Date:  2011-01       Impact factor: 84.694

Review 3.  G protein-coupled receptors as oncogenic signals in glioma: emerging therapeutic avenues.

Authors:  A E Cherry; N Stella
Journal:  Neuroscience       Date:  2014-08-24       Impact factor: 3.590

4.  ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease.

Authors:  Rainer Kuefer; Kathleen C Day; Celina G Kleer; Michael S Sabel; Matthias D Hofer; Sooryanarayana Varambally; Christoph S Zorn; Arul M Chinnaiyan; Mark A Rubin; Mark L Day
Journal:  Neoplasia       Date:  2006-04       Impact factor: 5.715

Review 5.  G Protein Coupled Receptor-mediated Transactivation of Extracellular Proteases.

Authors:  Allison E Schafer; Burns C Blaxall
Journal:  J Cardiovasc Pharmacol       Date:  2017-07       Impact factor: 3.105

6.  The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation.

Authors:  Abdo J Najy; Kathleen C Day; Mark L Day
Journal:  J Biol Chem       Date:  2008-04-22       Impact factor: 5.157

Review 7.  Roles of proteolysis in regulation of GPCR function.

Authors:  G S Cottrell
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

8.  Multiple mechanisms are responsible for transactivation of the epidermal growth factor receptor in mammary epithelial cells.

Authors:  Karin D Rodland; Nikki Bollinger; Danielle Ippolito; Lee K Opresko; Robert J Coffey; Richard Zangar; H Steven Wiley
Journal:  J Biol Chem       Date:  2008-09-09       Impact factor: 5.157

9.  A novel signaling pathway of tissue kallikrein in promoting keratinocyte migration: activation of proteinase-activated receptor 1 and epidermal growth factor receptor.

Authors:  Lin Gao; Lee Chao; Julie Chao
Journal:  Exp Cell Res       Date:  2009-10-30       Impact factor: 3.905

10.  Activated protein C enhances cell motility of endothelial cells and MDA-MB-231 breast cancer cells by intracellular signal transduction.

Authors:  Mark W Gramling; Lea M Beaulieu; Frank C Church
Journal:  Exp Cell Res       Date:  2009-11-03       Impact factor: 3.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.